|
Gene: ANKRD31 |
Gene summary for ANKRD31 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ANKRD31 | Gene ID | 256006 |
Gene name | ankyrin repeat domain 31 | |
Gene Alias | ANKRD31 | |
Cytomap | 5q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8N7Z5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256006 | ANKRD31 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.99e-03 | 1.12e-01 | -0.1464 |
256006 | ANKRD31 | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.59e-04 | 1.59e-01 | -0.059 |
256006 | ANKRD31 | HTA11_4255_2000001011 | Human | Colorectum | SER | 4.39e-32 | 1.60e+00 | 0.0446 |
256006 | ANKRD31 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.20e-35 | 2.27e+00 | 0.0131 |
256006 | ANKRD31 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.11e-50 | 2.75e+00 | 0.0112 |
256006 | ANKRD31 | HTA11_11156_2000001011 | Human | Colorectum | AD | 2.94e-21 | 1.45e+00 | 0.0397 |
256006 | ANKRD31 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.13e-68 | 2.66e+00 | 0.0588 |
256006 | ANKRD31 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.13e-100 | 2.29e+00 | 0.3859 |
256006 | ANKRD31 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.30e-130 | 2.81e+00 | 0.3005 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
GO:00457871 | Colorectum | MSS | positive regulation of cell cycle | 80/3467 | 313/18723 | 1.15e-03 | 1.12e-02 | 80 |
GO:0090068 | Colorectum | MSS | positive regulation of cell cycle process | 60/3467 | 236/18723 | 5.01e-03 | 3.46e-02 | 60 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD31 | SNV | Missense_Mutation | c.3781N>A | p.Ala1261Thr | p.A1261T | Q8N7Z5 | protein_coding | tolerated(0.05) | probably_damaging(0.994) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANKRD31 | SNV | Missense_Mutation | c.3530N>T | p.Ser1177Phe | p.S1177F | Q8N7Z5 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ANKRD31 | SNV | Missense_Mutation | c.4066N>T | p.Asp1356Tyr | p.D1356Y | Q8N7Z5 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKRD31 | SNV | Missense_Mutation | c.3190N>A | p.Glu1064Lys | p.E1064K | Q8N7Z5 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKRD31 | SNV | Missense_Mutation | c.1233G>T | p.Lys411Asn | p.K411N | Q8N7Z5 | protein_coding | tolerated(0.06) | benign(0.012) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD | |
ANKRD31 | SNV | Missense_Mutation | novel | c.2735N>A | p.Ala912Asp | p.A912D | Q8N7Z5 | protein_coding | deleterious(0.01) | benign(0.033) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANKRD31 | SNV | Missense_Mutation | c.3338C>G | p.Ser1113Cys | p.S1113C | Q8N7Z5 | protein_coding | deleterious(0.01) | benign(0.045) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANKRD31 | SNV | Missense_Mutation | novel | c.2475N>T | p.Glu825Asp | p.E825D | Q8N7Z5 | protein_coding | tolerated(0.23) | benign(0) | TCGA-BH-A0HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ANKRD31 | SNV | Missense_Mutation | c.887N>C | p.Leu296Ser | p.L296S | Q8N7Z5 | protein_coding | tolerated(0.06) | benign(0.211) | TCGA-BH-A18J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
ANKRD31 | SNV | Missense_Mutation | c.5551N>A | p.Glu1851Lys | p.E1851K | Q8N7Z5 | protein_coding | deleterious(0) | possibly_damaging(0.818) | TCGA-E2-A14Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |